Last reviewed · How we verify
ATRIPLA^TM
Non-nucleoside reverse transcriptase inhibitor
Non-nucleoside reverse transcriptase inhibitor Used for HIV-1 infection.
At a glance
| Generic name | ATRIPLA^TM |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Non-nucleoside reverse transcriptase inhibitor |
| Target | HIV-1 reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
ATRIPLA is a fixed-dose combination of efavirenz, emtricitabine, and tenofovir disoproxil fumarate. It works by inhibiting the replication of HIV-1.
Approved indications
- HIV-1 infection
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |